trending Market Intelligence /marketintelligence/en/news-insights/trending/hEFMAoLpugPu__iqr73d7w2 content esgSubNav
In This List

Ono Pharmaceutical's fiscal Q1 profit slips YOY despite increase in revenue

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Ono Pharmaceutical's fiscal Q1 profit slips YOY despite increase in revenue

Ono Pharmaceutical Co. Ltd. reported fiscal first-quarter consolidated profit attributable to shareholders of ¥11.77 billion, or ¥22.31 per share, down from ¥13.68 billion, or ¥25.81 per share in the year-ago period.

Revenue for the three months from April through June reached ¥60.91 billion, up from ¥58.76 billion in the previous year. The company's revenue from Japan fell year over year to ¥48.40 billion from ¥53.70 billion, and rose in the Americas and Asia during the period.

Ono booked ¥14.94 billion in research and development costs during the quarter, up from ¥11.12 billion in the year-ago period.

Sales for the cancer blockbuster drug Opdivo jumped 21.4% to ¥19.80 billion in the quarter and are expected to reach ¥74.0 billion for the full fiscal year ending March 31, 2018.

The Japanese pharmaceutical company confirmed its outlook for the full fiscal year: attributable profit of ¥29.0 billion, or ¥54.72 per share, and revenue of ¥236.0 billion.

For the the first six months of the fiscal year, Ono expects revenue to reach ¥112.50 billion with profit attributable to shareholders of ¥10.70 billion, or ¥20.19 per share.

As of Aug. 1, US$1 was equivalent to ¥110.15.